JNCCN 360 - Bladder - Ongoing CE Activities

Editor:

Thomas Flaig, MD

Advertisement

Advertisement

Ongoing CE Activities

Bringing Patients to the Forefront of Bladder Cancer Care

Cabozantinib Shows Activity in Metastatic Urothelial Carcinoma

Emerging Paradigms in Advanced/Metastatic Urothelial Cancer: What Are the Implications to Practice?

Metastatic Urothelial Carcinoma: 2020 Multidisciplinary Molecular Tumor Board

New Therapeutic Developments In Urothelial Cancer: Clinical Trial Evidence And Expert Guidance

Newly Approved Agents for Patients with Metastatic Urothelial Bladder Carcinoma Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

Oncology Today with Dr Neil Love: Immune Checkpoint Inhibitors in Urothelial Bladder Carcinoma

Oncology Today with Dr Neil Love: Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer

Sections

NCCN Resources

Copyright © 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.